Pharmacogenomic Services-Technology

Dilution analysis of low-level EGFR mutations in NSCLC (Non-Small Cell Lung Cancer) patients are easily detected to <1% by TRANSGENOMIC’s WAVE and SURVEYOR Nuclease technologies but missed by sequencing (A). Only after WAVE/SURVEYOR fractionation, were mutations confirmed by sequencing (B). *Two fragments generated by SURVEYOR Nuclease digestion caused by a mutation and 8a SNP occurrence identified in the second SURVEYOR cut in EGFR exon 21.¹

¹Figure reproduced with permission from Pasi A. Janne, et. al: A Rapid and Sensitive Enzymatic Method for Epidermal Growth Factor Receptor Mutation Screening, Clin Cancer Res, 2006;12(3) Feb 1, 2006. Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, D1234, 44 Binney Street, Boston, MA 02115.